Knockout of Wnt5a in host cells dramatically reduces tumor burden and alters immune infiltration patterns, suggesting that targeting Wnt5a or its downstream effector, Fgr, may be an effective therapeutic strategy for halting ovarian cancer metastasis (46). Here, WNT5A is linked to ovarian carcinoma.